The Pediatric Market Needs Numbers, Not Just Ideas

There is so much promise in the pediatric device market. However, what is currently being said needs to be explained even deeper. 

Currently, the benefits of building in the pediatric device market include:

• less competition

• more market share

• shorter clinical trials

• higher margins

One that needs to be explained deeper how to understand these advantages numerically. Below is an example which can be applied to any startup thinking about doing a device in a pediatric market.

Two Whiteboards

• You're deciding between two options: Adult Spine (~$12–15 billion market) vs. Pediatric Spine (~$42–98 million market)

• On paper, adult looks like the obvious choice (bigger market, bigger opportunity)

Exhibit One: Who controls the price?

• The formula: (P−MC)/P = 1/|Elasticity|. This means fewer alternatives for customers = more pricing power for you

• In 2025, Stryker sold off its entire U.S. spine implant business to chase higher-margin software/navigation instead. Here, a major player fled hardware margin

• The first pediatric magnetic growing-rod company grew revenue from $26M → $40M in one year (54%), with zero price competition, because no one else made the device

• Takeaway: One market's biggest player is running from the margin. The other's only player never had to defend it.

Exhibit Two: How crowded is the room?

• The formula: HHI = sum of each competitor's market share, squared

• Near 10,000 = one company owns it. Under 1,500 = genuinely competitive.

• ✅ Confirmed (pediatric): One company holds 95.3% of the growing-rod market → HHI ≈ 9,090

• ⚠️ Your estimate (adult): Sources disagree on who's #1 and #2 (one says Medtronic + Globus = 42%, another says Medtronic + J&J = 45%+), but both agree the top 5 hold 62%. Building from that, your estimate lands around HHI 1,000–1,200 (moderately crowded, not the tight duopoly the headlines suggest)

• Takeaway: Pediatric is a near-monopoly, confirmed. Adult is only moderately concentrated, estimated.

Exhibit Three: How big a slice can you actually take?

• The formula: realistic share ≈ 1 ÷ (number of competitors + 1)

• ⚠️ Your estimate (adult): Counting every named competitor across multiple reports (Medtronic, Globus, J&J, Zimmer Biomet, VB Spine, Alphatec, Orthofix, SeaSpine, and more) gives roughly 15–20 players → your realistic share as a new entrant: under 1%, before even accounting for their existing hospital relationships

• At launch, there was effectively no other competitor in the room

• Takeaway: In adult spine, you're fighting for scraps. In pediatric, you're deciding how big to make the whole pie.

The Verdict

• Formula: Profit = TAM × Your Share × Your Margin − Fixed Costs

• Adult spine: huge TAM, near-zero realistic share, margin under pressure

• Pediatric spine: small TAM, share that can approach 100%, real margin, cheaper to get there

Exhibit A: The Proof (this already happened)

• The first pediatric growing-rod company was acquired for $380M + $30M milestones = $410M total, against $40M revenue: about 10x

• That's not because the niche itself got huge. It was $41.7M globally in 2025 (~a decade after the deal) and is only forecast to hit $97.6M by 2035 (two decades out). Both numbers stay under $100M.

• The buyer said explicitly it wanted to extend the technology into much bigger adult markets

• Takeaway: The small pediatric niche wasn't the destination. It was the proof of concept that made the bigger bet believable